DAPA ACT HF-TIMI 68

DAPA ACT HF-TIMI 68 is an investigator-initiated, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (LVEF ≤40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin on the clinical outcome of cardiovascular death or worsening heart failure.

DAPA ACT HF-TIMI 68 trial schema 2020-03-06

DAPA ACT HF on ClinicalTrials.gov

CONTACT US about DAPA ACT HF

PUBLICATIONS

Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2021 Feb 17. doi: 10.1001/jamacardio.2020.7585.

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close